The Chronic Lower Back Pain (CLBP) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Lower Back Pain: An Overview
Chronic low back pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is very common, and at one point, everyone must have faced this problem. Lower back pain that is long-term (for more than 3 months) is called CLBP.
This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe. CLBP is the second leading cause of disability worldwide, being major welfare and economic problem.
This condition affects men and women in all ethnic groups equally. This disease also leads to stress, depression, and anxiety. CLBP has adverse physical and psychological repercussions. It creates a significant economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments.
Chronic Lower Back Pain (CLBP) Market Key Facts
-
The total prevalent population of CLBP in the 7MM was 76,440,725 in 2020. These cases of CLBP in the 7MM is expected to increase during the forecasted period i.e., 2021–2032.
-
Among all the seven major markets, the United States accounts for the highest number of cases of CLBP. There were 31,553,732 diagnosed prevalent cases reported in 2020, in the US.
-
In the EU-5 countries, amongst the CLBP population, Spain had the highest prevalent population of CLBP with 8,796,892, followed by the UK which had 5,986,047 cases in 2020.
-
Out of the total diagnosed prevalent population of CLBP in the US in 2020, 14,262,287 cases were found in males whereas 17,291,445 cases were found in females. The total diagnosed prevalent population of CLBP in the 7MM was 68,047,135 in 2020.
Chronic Lower Back Pain (CLBP) Market
CLBP is a disorder that affects both males and females, majorly from the elderly age groups. It is one of the leading causes of disability around the globe. This condition puts an immense social and economic impact on the patient. CLBP has different associated risk factors that can contribute to the increased prevalence.
As per DelveInsight, the Chronic Lower Back Pain market size was found to be USD 6,227 million in 2020, which is expected to increase during the forecast period. The increase in Market Size is a direct consequence of the expected launch of potential therapies, along with great competition among various companies and a precision approach that will lead to more effective therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Lower Back Pain market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Chronic Lower Back Pain market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Chronic Lower Back Pain (CLBP) Epidemiology
The epidemiology section covers insights about the historical and current Chronic Lower Back Pain patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Lower Back Pain Epidemiology Segmentation
-
Total Prevalence of CLBP
-
Total Diagnosed Prevalence of CLBP
-
Gender-specific Diagnosed Prevalence of CLBP
-
Age-specific Diagnosed Prevalence of CLBP
Chronic Lower Back Pain (CLBP) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched in the market during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chronic Lower Back Pain Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Chronic Lower Back Pain Therapeutics Analysis
There are many different drug candidates under investigation, falling into different classes of therapies that are prescribed for the treatment of CLBP patients. There are some novel therapies also that are being studied that not only provide symptomatic relief but also work on the cause of the condition.
Some of the key companies in the Chronic Lower Back Pain Market include:
-
Mesoblast Limited
-
Scilex Holding
-
Camurus/Braeburn
-
AnGes MG
And many others
Chronic Lower Back Pain Therapies covered in the report include
-
Brixadi (CAM2038/buprenorphine injection depot)
-
Semdexa (SP-102, dexamethasone sodium phosphate)
-
Rexlemestrocel-L
-
AMG0103
And many other
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Lower Back Pain Competitive Intelligence Analysis
4. Chronic Lower Back Pain Market Overview at a Glance
5. Chronic Lower Back Pain Disease Background and Overview
6. Chronic Lower Back Pain Patient Journey
7. Chronic Lower Back Pain Epidemiology and Patient Population
8. Chronic Lower Back Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Lower Back Pain Unmet Needs
10. Key Endpoints of Chronic Lower Back Pain Treatment
11. Chronic Lower Back Pain Marketed Products
12. Chronic Lower Back Pain Emerging Therapies
13. Chronic Lower Back Pain Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Lower Back Pain Market Outlook (7 major markets)
16. Chronic Lower Back Pain Access and Reimbursement Overview
17. KOL Views on the Chronic Lower Back Pain Market.
18. Chronic Lower Back Pain Market Drivers
19. Chronic Lower Back Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
Other Trending Healthcare Reports By DelveInsight
As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of the key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/